Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in adolescents with chronic migraine
NCT04965675Phase 3Recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2021
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of eptinezumab in chronic migraine, sponsored by Lundbeck. Started Jun 2021; status: recruiting.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT04965675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965675.